Loading stock data…
Bright Minds Biosciences Inc (DRUG)
$71.33+0.04 (+0.06%)
Market ClosedLast close Jul 24
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bright Minds Biosciences Inc. in the Healthcare sector is trading at $71.33 with a market capitalization of $564M. Wall Street consensus targets $166.74 (3 analysts), implying a +133.8% move over the next 12 months. The stock is currently 42% below its 52-week high of $123.75, remaining 5.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +133.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.32M↓ | -$6.90M↓ | -$5.66M↓ | -$3.30M↑ | -$3.35M |
| Net Income | -$10.46M↓ | -$7.57M↓ | -$4.09M↑ | -$5.24M↓ | -$2.95M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epile...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$563.85M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-8.87%
Volume
Today's trading volume
345,508
Recent News
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?
Bright Minds Biosciences Inc (NASDAQ:DRUG) is among the best psychedelic stocks to buy in 2026. The company has multiple psychedelic drug candidates, including potential medicines for epilepsy. Its flagship product candidate is BMB-101, which is being developed as a treatment for absence epilepsy. On March 5, H.C. Wainwright weighed on Bright Minds Biosciences Inc. (NASDAQ:DRUG) […]
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, FDA alignment and a DSMB recommendation. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential HELUS PHARMA REPORTS PHASE 2 HLP004 RESULTS: Helus Pharma (HELP) announced Thursday topline results from a Phase